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Balloon Dilation and Stent
Implantation for Treatment
of Femoropopliteal Arterial
Disease: Meta-Analysis1
PURPOSE: To perform a meta-analysis of long-term results of balloon dilation and
stent implantation in the treatment of femoropopliteal arterial disease.
MATERIALS AND METHODS: The English-language literature was searched for
studies published between 1993 and 2000. Inclusion criteria for articles were presen-
tation of long-term primary patency rates, standard errors (explicitly reported or deriv-
able), and baseline characteristics of the study population. Two reviewers independently
extracted data, and discrepancies were resolved by consensus. Primary patency rates
were combined by using a technique that allows adjustment for differences across study
populations. Analyses were adjusted for lesion type and clinical indication.
RESULTS: Nineteen studies met the inclusion criteria, representing 923 balloon
dilations and 473 stent implantations. Combined 3-year patency rates after balloon
dilation were 61% (standard error, 2.2%) for stenoses and claudication, 48%
(standard error, 3.3%) for occlusions and claudication, 43% (standard error, 4.1%)
for stenoses and critical ischemia, and 30% (standard error, 3.7%) for occlusions
and critical ischemia. The 3-year patency rates after stent implantation were 63%–
66% (standard error, 4.1%) and were independent of clinical indication and lesion
type. Funnel plots demonstrated an asymmetric distribution of the data points
associated with stent studies.
CONCLUSION: Balloon dilation and stent implantation for claudication and stenosis
yield similar long-term patency rates. For more severe femoropopliteal disease, the
results of stent implantation seem more favorable. Publication bias could not be
ruled out.
Treatment and prognosis of peripheral arterial disease is influenced by lesion and patient
characteristics, such as the site of the lesion, type of lesion (stenosis or occlusion, lesion
length), arterial runoff, and clinical manifestation (1). Estimates of the 5-year patency rate
of balloon dilation for femoropopliteal arterial disease range from as low as 12% in patients
with an occlusion and critical ischemia to 68% in patients with a stenosis and claudication
(2). Bypass surgery for femoropopliteal arterial disease is associated not only with higher
long-term patency rates but also with a higher procedural morbidity, mortality, and a
longer hospital stay (3). The development of a new therapy that combines the relatively
low risk of an endovascular procedure with a higher patency rate than those currently
associated with balloon dilation would be desirable.
In the recent past, many new endovascular techniques, such as laser-assisted balloon
angioplasty and atherectomy, as well as several types of stents, have been developed and
tested (4–10). Until now, however, these devices have not demonstrated improvement in
the long-term results of balloon dilation in the femoropopliteal artery. Of these tech-
niques, only stent placement is currently used, and it is used only as a “bailout” procedure
after a failed balloon dilation procedure.
At present, new endovascular stent-graft systems are being developed (8,11,12). To
enable comparison of the results of a new therapy with established therapies, data on
benefits and costs of the established procedures must be available. To our knowledge, the
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last meta-analysis on the long-term re-
sults of femoropopliteal balloon dilation
dates from 1993 and did not consider
femoropopliteal stent implantation (2).
Although major improvements in the
long-term results of balloon dilation
seem unlikely, the use of stents as an
adjunct to balloon dilation may have im-
proved the patency rate of percutaneous
revascularization. Furthermore, the con-
tinuous development and improvement
of materials and skills, as well as possible
changes in the indications for perform-
ing balloon dilation, may have influ-
enced the long-term results.
The aim of this study was to review the
currently available data on the long-term
results following balloon dilation and to
assess the influence of stent placement in
the treatment of femoropopliteal arterial
disease.
MATERIALS AND METHODS
Data Sources
We performed a systematic review of
the literature that was published between
January 1993 and August 2000. We re-
stricted our review to this period for two
reasons. First, a previous meta-analysis
included balloon dilation articles that
were published between January 1985
and January 1993 (2). Second, we ex-
pected only a limited number of stent
implantation studies to have been pub-
lished before 1993, and these studies
were likely to be small (13). Whereas the
baseline analysis of the current meta-
analysis included studies published be-
tween January 1993 and August 2000, in
a sensitivity analysis we also included the
studies identified in the previous meta-
analysis (2).
To identify studies that were published
from 1993 to 2000, we performed a com-
prehensive search of abstracts of English-
language articles in the MEDLINE data-
base, using the search terms “interventional
radiology,” “balloon dilation,” “stents,” “ar-
terial occlusive diseases,” “arteriosclerosis,”
“claudication,” “ischemia,” “limb salvage,”
“femoropopliteal,” “femorodistal,” “femo-
ral,” “popliteal,” “infrainguinal,” “above-
knee,” “survival analysis,” “actuarial analy-
sis,” “patency,” “patencies,” “life table,”
“failure rate,” “follow-up studies,” and “re-
currence.”
In addition to the abstract search in
the MEDLINE database, references were
obtained from the bibliographies of re-
trieved articles. If the abstract of an arti-
cle provided sufficient information to
conclude that the authors did not report
results after femoropopliteal percutane-
ous transluminal angioplasty or stent
placement, the full article was not re-
trieved. These articles were excluded on
the basis of the abstract alone. All other
articles were retrieved and reviewed. To
avoid double counting, both data extrac-
tors (G.S.R.M. and J.L.B.) compared the
articles for participating institutions and
inclusion criteria. If overlap of study pop-
ulations was suspected, the most com-
plete report fulfilling the study selection
criteria (specified in the next section) was
included. Unpublished research was not
included.
Study Selection
Studies that reported data on the long-
term results after balloon dilation or
stent implantation were included if (a) at
least 90% of all procedures were per-
formed for femoropopliteal arterial dis-
ease, (b) primary patency data and stan-
dard errors were presented or such data
could be estimated from the data pre-
sented, (c) the study follow-up was at
least 1 year, (d) the number of subjects at
the start of follow-up was at least 20 pa-
tients, and (e) the number of initial fail-
ures was reported.
To adjust for differences in popula-
tions between studies, articles were re-
quired to include data on the case mix of
the study population. Since it is unlikely
that all articles report all relevant prog-
nostic factors to qualify for inclusion, we
required that authors reported a mini-
mum set of data on the case mix of the
study population that both were well-
known prognostic factors and were likely
to be reported in the majority of studies
(2). The minimum set consisted of clini-
cal indication (percentage with claudica-
tion vs percentage with critical ischemia)
and lesion type (percentage with stenosis
vs percentage with occlusion).
Data Extraction
Two readers (G.S.R.M. and J.L.B.) ab-
stracted the data from each article inde-
pendently by using a standard form. The
following data were recorded: (a) number
at risk at the start of the follow-up, (b)
percentage of subjects with claudication
versus percentage with critical ischemia
(rest pain and tissue loss), (c) percentage
of subjects with a stenosis versus percent-
age with an occlusion, and (d) patency
rates and standard errors or data suffi-
cient to derive patency rates and/or stan-
dard errors, such as life tables or survival
curves listing the number at risk at sev-
eral points in time. Furthermore, the fol-
lowing factors that may reflect differ-
ences in study populations and methods
between studies were extracted: (e) per-
centage of femoral lesions versus percent-
age of popliteal lesions, (f) percentage of
subjects with poor arterial runoff (one or
no patent crural vessel), (g) data on
length of the lesions, (h) methods and
criteria used for assessment of vascular
patency, and (i) unit of observation used
in reporting patency (ie, lesions, limbs,
procedures, or patients).
If the article reported a life table or a
patency curve listing the number at risk
at several time points but did not report
the standard errors, we estimated the
standard errors by using an actuarial life-
table approach and the Greenwood for-
mula (14). We assumed that where
stepped survival curves were used, the
lowest of the two data points at the end
of each interval represented the fraction
of patients at the end of that interval,
unless explicitly stated otherwise in the
methods section of the article.
Some articles reported multiple pa-
tency rates at the same point in time,
based on different definitions of patency.
To increase the uniformity in the defini-
tion of patency across the various studies,
we extracted the data associated with the
patency definition that corresponded
best with the criteria for a marked change
in clinical status following an interven-
tion for peripheral arterial disease that
were proposed by the Society for Vascular
Surgery and International Society for
Cardiovascular Surgery (SVS/ISCVS) (15).
Differences in the extracted data were
resolved in discussion. Only minor dis-
crepancies in the extracted data were
found. In most cases, these were small
differences in the patency rate extracted
from survival curves. The remaining dis-
crepancies were found to be due to mis-
interpretation of the reported data. Both
authors resolved these by examining the
articles together.
Funnel Plot
To detect the presence of publication
bias (ie, the bias resulting from the
greater likelihood of publication of stud-
ies reporting a positive result compared
with the likelihood for studies with a
negative result), we constructed a funnel
plot. In a funnel plot, a measure of the
study size is plotted as a function of the
measure of interest (16). In the current
study, we plotted the number of patients
that underwent femoropopliteal inter-
vention as a function of the reported
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1-year primary patency rate. If publica-
tion bias is absent, the distribution of the
data points will be symmetric and funnel
shaped. Visual inspection of the plot
may, however, reveal an asymmetric dis-
tribution of data points, which may re-
sult from a paucity of smaller studies re-
porting negative results. In that case, the
plot indicates the presence of publication
bias.
Data Synthesis
All patency rates reported at multiple
times were analyzed together by using
weighted multiple linear regression ac-
cording to the method described by Dear
(17). The dependent variable in the re-
gression models was the reported pa-
tency rate, and independent variables
were the times of the reported patency
rates. In the regression models, we ad-
justed for the correlation between the re-
ported patency rates within the same
study, and the inverse-squared standard
errors were used as weights. In the regres-
sion model, both balloon dilation and
stent implantation had their own time-
dependent treatment effect.
To adjust for differences in case mix
between the study populations, we in-
cluded the baseline characteristics of
clinical indication (claudication vs criti-
cal ischemia) and lesion type (stenosis vs
occlusion) in the model. Because the re-
sults after balloon dilation and stent im-
plantation may be affected differently by
clinical indication and lesion type, we
also included interaction terms that al-
lowed treatment-type–specific effects for
these factors.
The percentages of subjects with a fem-
oropopliteal occlusion and critical isch-
emia and who were undergoing stent im-
plantation were modeled as continuous
variables. With use of multivariate step-
wise backward regression, variables and
interaction terms with a P value larger
than .05 were eliminated. The models
were fitted with SAS PROC MIXED (SAS Sys-
tem for Windows, release 6.12; SAS Insti-
tute, Cary, NC).
Heterogeneity
To detect residual heterogeneity in the
reported patency rates that could be ex-
plained in terms of differences between
studies other than differences in the per-
centages of subjects with critical ischemia,
occlusion, or undergoing stent implantation,
an interaction term representing study ef-
fects within the two treatment groups was
added to the model and tested in a multivar-
iate analysis. We found that heterogeneity
was present in the model. Therefore, addi-
tional explanatory variables—namely, age,
sex, lesion site, status of distal arteries, long-
term use of oral anticoagulant treatment af-
ter intervention, definition of patency, and
unit of observation used in reporting pa-
tency—were tested with multivariate analy-
ses for their contribution to the explanation
of reported heterogeneity in treatment effect.
Only those studies that reported data on the
covariables incorporated in the regression
model were included in each of these
analyses.
Sensitivity Analyses
To test for the dependence of results on
the patency rates reported in a single
study, sensitivity analyses were per-
formed by analyzing the data with a jack-
knife type of procedure; that is, the anal-
ysis was repeated multiple times, each
time with removal of a single study from
the baseline group of studies.
Second, to explore the robustness of our
results and to detect a trend in reported
patency results over time, we extended our
data set with the articles identified in the
previous meta-analysis (2) that met our in-
clusion criteria. These additional articles
were all balloon dilation studies. To iden-
tify the trend in patency rates over time, a
term representing the year of publication
was added to the model. This variable was
modeled as a continuous variable and in
another analysis as a dummy variable (score
of 0 for studies identified in the previous
meta-analysis, score of 1 for studies identified
in the current study). All variables were
tested at a significance level of .05.
Third, in an additional sensitivity anal-
ysis, we investigated the influence of pri-
mary stent implantation on our patency
estimates by excluding the two studies
that reported primary stent implantation
results (10,18).
Finally, in some studies, patency re-
sults were reported separately for patients
with occlusions and for patients with ste-
noses (19–21). In most studies, however,
patency results were reported for stenoses
and occlusions combined. To explore the
effect on our results of inclusion of the
overall patency results instead of the re-
sults by subgroups, we performed a sen-
sitivity analysis using, where available,
the patency data by subgroups.
RESULTS
Selected Articles
A total of 533 citations published be-
tween January 1993 and August 2000
were screened. Of these, 118 articles were
retrieved, of which 19 articles met the
inclusion criteria. The abstracts of 415
articles provided sufficient information
to conclude that the authors did not re-
port results following femoropopliteal
percutaneous transluminal angioplasty
or stent placement. These articles were
excluded on the basis of the abstract. Of
the 118 articles that were retrieved, 99
were excluded for the following reasons:
(a) combined analysis of treatment of
multiple arterial segments (n 5 18), (b)
missing data on lesion type or clinical
indication (n 5 6), (c) overlap of study
population (n 5 5), (d) insufficient data
to extract the patency rates or standard
errors (n 5 25), (e) missing data on initial
failures (n 5 6), (f) study sample of fewer
than 20 patients (n 5 7), (g) study fol-
low-up of less than 1 year (n 5 5), (h)
focus on other percutaneous translumi-
nal treatments such as laser-assisted per-
cutaneous transluminal angioplasty or
atherectomy (n 5 23) or on the natural
history of femoropopliteal arterial disease
(n 5 1), (i) not in the English language
(n 5 2), and (j) letter to the editor (n 5 1).
Of the 19 studies included, three in-
volved the same authors (9,10,22). Over-
lap could be excluded in one article be-
cause the recruitment period did not
overlap (22). In the other two articles, the
authors reported overlap in inclusion pe-
riod (9,10). In one of the articles, how-
ever, the authors analyzed only patients
with a femoropopliteal occlusion (62 pa-
tients), whereas in the other, the authors
analyzed patients with stenoses, with the
exception of two cases out of 35, imply-
ing that the maximum overlap, if any,
was two cases.
Review
The extracted data from the articles an-
alyzed (9,10,18–34), ordered by publica-
tion year, are outlined in Tables 1 and 2.
We identified one randomized trial (10)
in which stent implantation was com-
pared with balloon dilation and 18 non-
comparative studies, including nine fo-
cused on balloon dilation, seven focused
on stent implantation, and two in which
both balloon dilation and stent implan-
tation procedures were analyzed together
in a single cohort (29,30).
Follow-up periods and baseline charac-
teristics of the study populations differed
markedly across the 19 studies. Fol-
low-up varied from 1 to 5 years. Overall,
the follow-up after stent implantation
was shorter than the follow-up after bal-
loon dilation. The percentage of cases
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with an occlusion varied from 6% to
100%, and the percentage of cases with
critical ischemia varied from 0% to 56%.
Primary stent implantation was per-
formed in two studies (10,18) (Table 2).
In the remaining studies, the majority of
stent implantations were performed after
a failed balloon dilation. In the balloon
dilation studies, the authors of one arti-
cle reported specifically that only pa-
tients undergoing repeat balloon dilation
were included, whereas in the other bal-
loon dilation studies, this criterion was
not selected (23). In one study, the au-
thors included only patients with a lesion
length larger than 10 cm (25). All other
studies included mainly patients with le-
sions smaller than 10 cm.
The published standard for evaluating
results of interventional therapy for pe-
ripheral arterial disease as proposed by
the SVS/ISCVS (15) was used as a refer-
ence in 17 of 19 articles. The authors
classified the results extracted from these
articles by using the SVS/ISCVS criteria
for a marked change in clinical status in 11
articles (9,10,18,21–24,27,31,33,34) and for
patency in six articles (20,25,26,38,30,32).
The authors of the remaining two articles did
not refer to these standards but used a classi-
TABLE 1
Review of Study Population Characteristics and Patency Results of Studies that Included Femoropopliteal Balloon Dilation
Study* Year
No. of
Patients
Age
(y)†
Sex
(%)‡
Critical
Ischemia
(%)
Occlusion
(%)
Poor
Runoff
(%)
Popliteal
Location
(%)
Patency Rate (%)
0-year 1-year 2-year 3-year 4-year 5-year
Standard
Error§
Treiman et al (23) 1994 35 69 57/43 20 17 46 49 94 41 24 11 11 11 10
Becquemin et al (19) 1994 95 67 64/36 31 45 52 16 79 60 51 NA NA NA 6
Jeans et al (24) 1994 137 65 72/28 44 65 NA NA 90 60 53 52 51 50 6
Vroegindeweij et al (22) 1995 62 64 73/27 2 100 23 NA 82 63 56 46 46 46 9
Murray et al (25) 1995 42 74 50/50 11 59 33 NA 93 86 53 NA NA NA 26
Tielbeek et al (9) 1996 35 64 77/23 0 6 0 NA 100 80 67 62 62 62 10
Stanley et al (26) 1996 176 69 55/45 26 41 31 16 73 58 46 38 30 26 8
Vroegindeweij et al (10)\ 1997 27 64 70/30 0 19 11 NA 89 85 NA NA NA NA 7
Martin et al (27) 1999 88 NA 52/48 26 6 NA 14 NA 62 57 57 44 37 7
Golledge et al (28) 1999 74 73 62/38 42 26 28 NA 90 58 NA NA NA NA 6
O’Donohoe et al (29)# 1999 96 69 57/43 56 46 NA NA 84 53 NA NA NA NA 5
Karch et al (30)** 2000 85 56 48/52 36 7 38 25 97 74 62 56 52 52 13
Note.—NA 5 not available.
* Number in parentheses is the reference number.
† Mean or median age, depending on what authors reported.
‡ Data are percentage of male/female.
§ Standard error of last available patency rate only.
\ Balloon dilation arm of randomized clinical trial to compare femoropopliteal stent placement with balloon dilation.
# Analyzed 70 balloon dilations and 30 stent placements together in one cohort.
** Analyzed five stent deployments after failed balloon dilation and 108 balloon dilations together.
TABLE 2
Review of Study Population Characteristics and Patency Results of Studies that Included Femoropopliteal
Stent Implantation
Study* Year
No. of
Patients
Age
(y)†
Sex
(%)‡
Critical
Ischemia
(%)
Occlusion
(%)
Poor
Runoff
(%)
Popliteal
Location
(%)
Patency Rate (%)
0-year 1-year 2-year 3-year 4-year 5-year
Standard
Error§
Martin et al (31) 1995 90 64 64/36 23 35 0 0 99 61 49 NA NA NA 5
White et al (32) 1995 32 65 72/28 6 47 47 31 97 72 63 63 NA NA 38
Henry et al (20) 1995 116\ 62 87/13 7# 33 9 0 100 81 73 72 65 NA 8
Bergeron et al (33) 1995 39 64 85/15 21 57 33 0 95 81 77 77 NA NA 10
Chatelard et al
(34) 1996 35 70 54/46 37 29 46 26 100 80 76 76 NA NA 8
Vroegindeweij et al
(10)** 1997 24 65 71/29 0 17 8 NA 100 74 NA NA NA NA 9
Strecker et al (21) 1997 80 64 73/27 16 59 38 24 100 59 48 48 NA NA 11
Cheng et al (18)†† 1999 28 70 67/33 42# 39 NA 0 90 60 54 27 NA NA 22
Note.—NA 5 not available.
* Number in parentheses is the reference number.
† Mean or median age, depending on what authors reported.
‡ Data are percentage of male/female.
§ Standard error of last available patency rate only.
\ Number of patients not reported; authors reported data as number of limbs or number of procedures.
# Percentage of patients with critical ischemia was based on larger population that also included patients who underwent iliac intervention.
** Stent implantation arm of randomized clinical trial to compare femoropopliteal stent implantation with balloon dilation. Includes primary stent
implantations.
†† Includes primary stent implantations. Number of patients who underwent femoropopliteal intervention was derived from the number of
femoropopliteal lesions and the ratio of total number of patients to total number of lesions.
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fication system that met the SVS/ISCVS cri-
teria for a marked change in clinical status
(29) or for patency (19).
Long-term oral anticoagulant treat-
ment after the intervention was given
to patients for 3 months in both arms of
the randomized clinical trial (10) and for
6 months in one stent study (31). The
authors of another stent study reported
use of oral anticoagulant treatment dur-
ing the first half of the study period with
a gradually reducing dose but replaced
this with treatment by means of platelet
inhibitors (34). Platelet inhibitors, such
as aspirin, ticlopidine, or dypidamole,
were prescribed to patients after the in-
tervention in all but two studies. The
authors of these two studies did not re-
port data on medication following the
intervention (24,27). Overall, the results
in 923 patients undergoing balloon dila-
tion and 473 patients undergoing stent
implantation were included in the anal-
yses.
Funnel Plot
To detect publication bias, we con-
structed two funnel plots (Fig 1), one for
balloon dilation studies and one for stent
implantation studies. The distribution of
data points for the balloon dilation stud-
ies seems fairly symmetric and funnel
shaped and does not raise any suspicion
of the presence of publication bias. The
distribution of data points of the funnel
plot for stent implantation studies, how-
ever, is asymmetric, indicating that pub-
lication bias may be present.
Pooled Results
The initial model incorporated main
effects for time, treatment type, clinical
indication, and type of lesion, as well as
interaction terms to account for treat-
ment-specific patency over time and
treatment-specific effects for clinical in-
dication and type of lesion. In a multi-
variate analysis, all of these effects were
statistically significant.
Tables 3 and 4 and Figure 2 present
estimates of the patency rates for sub-
groups of patients. Clinical indication
and lesion type were statistically signifi-
cant variables in explaining the observed
heterogeneity in reported patency rates
(P , .001 and P 5 .001, respectively). The
3-year patency rate following balloon di-
lation ranged from 61% to 30%, depend-
ing on clinical indication and lesion
type. The 3-year patency rates following
stent implantation ranged from 66% in
patients with claudication and a stenosis
to 63% in patients with critical ischemia
and an occlusion; these rates were not
substantially affected by clinical indica-
tion and lesion type (Fig 2). Balloon dila-
tion and stent implantation yielded sim-
ilar patency rates in the treatment of
claudication and a femoropopliteal ste-
nosis (respective 3-year patency rates,
61% [standard error, 2%] and 66% [stan-
dard error, 3%]; Fig 2, A) but significantly
different patency rates in the treatment
of occlusions (P 5 .02; Fig 2, B), and crit-
ical ischemia, (P 5 0.01; Fig 2, C, D).
The estimated 5-year patency rates as-
sociated with balloon dilation were 55%
in patients with claudication and a ste-
nosis, 42% in those with claudication
and an occlusion, 38% in those with crit-
ical ischemia and a stenosis, and 25% in
those with critical ischemia and an occlu-
sion. The 5-year patency results for stent
implantation were not reported.
Heterogeneity
To test for residual heterogeneity, a
term representing study-specific effects
within the two treatment groups was
added to the model. This term was statis-
tically significant in the multivariate
analysis (P 5 .04), indicating that resid-
ual heterogeneity was present and that
part of the variability between studies in
reported patency rates could be ex-
plained by differences between studies
other than differences in the percentages
of occlusions, critical ischemia, and treat-
ment type.
To identify variables that may help ex-
plain some of the residual heterogeneity,
additional covariables representing base-
line characteristics of the study popula-
tions—namely, age (data available in 18
of 19 studies), gender (data available in
all studies), arterial runoff (data available
in 15 studies), use of long-term anticoag-
ulant treatment versus platelet inhibitor
treatment (data available in 17 studies),
and popliteal versus femoral localization
of the lesion (data available in 12 stud-
ies)—were tested in a multivariate model.
Furthermore, to determine whether the
differences in classification of outcome
may have significantly contributed to the
observed heterogeneity, an additional
variable representing SCS/ISCVS patency
versus SCS/ISCVS symptomatic outcome
was added to the model. This variable
was not associated with a statistically sig-
nificant regression parameter (P 5 .5).
Only the variable “age” had a statistically
significant contribution in explaining
the reported variation in patency rates
(P 5 .04). A 10-year increase in age was
associated with a 3.3% decrease in pri-
mary patency.
Sensitivity Analyses
The jackknife sensitivity analysis, in
which all articles were excluded one by
one from the baseline group, did not
show a large effect on long-term out-
come. The ranges found are shown in
Table 3. When a report of repeat balloon
dilation results (23) was excluded, the
3-year patency rate after balloon dilation
for claudication and stenosis increased
from 61% to 68% (standard error, 2.2%).
Exclusion of the one study that focused
on treatment of long lesions (26) did not
improve long-term patency rates associ-
ated with balloon dilation (maximum ab-
solute increase in long-term patency,
3%).
In a second sensitivity analysis, we ex-
tended the baseline group of studies by
Figure 1. Funnel plot shows cumulative 1-year primary patency
rates versus the number of patients included in the study. The distri-
bution of data points associated with balloon dilation (E) appears
fairly funnel shaped and symmetric, indicating that the presence of
publication bias is unlikely. The distribution of data points associated
with stent implantation (n ) is asymmetric, indicating that publica-
tion bias cannot be excluded.
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including those from the previous meta-
analysis (all balloon dilation studies pub-
lished between 1985 and 1993 [2]) that
met our inclusion criteria. The results fell
within the ranges of patency rates that
are shown in Tables 3 and 4. To test
whether the time period during which
the studies were performed may help ex-
plain the influence on our results, we ex-
tended the model with a variable that
represented the year of publication of the
articles. This variable, however, showed
no statistically significant explanatory
value.
In an additional sensitivity analysis,
we excluded the primary stent studies
(10,18) from the analysis. This resulted in
slightly lower patency rates for stent im-
plantation (absolute difference in 3-year
patency rates, 1%–3%). Finally, we ex-
plored the effect on our results of includ-
ing patency reported for separate sub-
groups (19–21) instead of overall patency
rates. This did not change the results sub-
stantially (all absolute differences were
smaller than 3%).
DISCUSSION
The current study represents a meta-anal-
ysis that combined the reported long-
term results associated with balloon
dilation and stent implantation for treat-
ment of femoropopliteal arterial disease
by using a weighted multiple linear re-
gression model. We found similar long-
term patency rates for stent implantation
and balloon dilation in the treatment of
claudication caused by a femoropopliteal
stenosis, but when the clinical indication
was critical ischemia or the lesion type
was an occlusion, long-term patency re-
sults were better with stent placement.
The results of sensitivity analyses, for ex-
ample, in which studies were excluded
one by one from the pooled sample,
showed that our results were relatively
independent of any one particular study.
The robustness of our estimates of long-
term outcome after balloon dilation was
also demonstrated in the sensitivity anal-
ysis that included studies identified in
both the current study and in a previous
meta-analysis (2).
Caution must be exercised, however,
when interpreting the results. This study
was limited by several factors. First, our
results may have been affected by publi-
cation bias; that is, the greater likelihood
of publication of results based on large
sample sizes or of positive results. We
constructed funnel plots to evaluate the
presence of publication bias. These plots
were based on the number of patients
entering the cohort and the reported
1-year patency rates. These patency rates
were not adjusted for differences in study
populations. Nevertheless, the plot asso-
ciated with balloon dilation was symmet-
ric and funnel shaped and did not reveal
the presence of publication bias. The fun-
nel plot for stent implantation studies
was asymmetric, which implies that we
cannot exclude the possibility of publica-
tion bias among these studies. The distri-
bution of data points was not, however,
characteristic of the presence of publica-
tion bias and may be caused by the low
number of stent implantation studies
available for the current analysis.
Second, the results reported in articles
may be difficult to compare because the
study populations, study design, and re-
porting methods often differ. The meta-
analytical technique used in the current
study for aggregating patency data allows
the incorporation of covariables, which
makes it possible to correct for some of
the differences in baseline characteristics
between the studies. Adjustment for
these differences was limited, however,
because not all articles reported relevant
information or they used different re-
porting methods, precluding a meaning-
ful classification. In the current study, we
adjusted for clinical indication, lesion
type, and treatment type. The results of
the heterogeneity analysis demonstrated
that there was variability between studies
TABLE 3
Estimated Pooled Primary Patency Rates after Balloon Dilation and Stent
Implantation in Patients with Claudication
Lesion Type and
Year after Treatment
Balloon Dilation Stent Implantation
Patency (%)* Range (%) Patency (%)* Range (%)
Stenosis
0 100 (1.0) 98–100 100 (1.2) 99–100
1 77 (1.7) 78–80 75 (2.2) 73–79
2 66 (2.0) 63–71 67 (2.4) 65–71
3 61 (2.2) 55–68 66 (2.7) 64–70
4 57 (2.5) 54–63 NA NA
5 55 (2.8) 52–62 NA NA
Occlusion
0 88 (2.9) 81–94 99 (2.3) 92–100
1 65 (3.0) 55–71 73 (2.8) 69–75
2 54 (3.1) 45–61 66 (3.0) 61–68
3 48 (3.3) 40–55 64 (3.2) 59–67
4 44 (3.5) 36–53 NA NA
5 42 (3.7) 33–51 NA NA
Note.—Ranges are derived from sensitivity analyses. NA 5 not available.
* Number in parentheses is the standard error.
TABLE 4
Estimated Pooled Primary Patency Rates after Balloon Dilation and Stent
Implantation in Patients with Critical Ischemia
Lesion Type and
Year after Treatment
Balloon Dilation Stent Implantation
Patency (%)* Range (%) Patency (%)* Range (%)
Stenosis
0 83 (3.7) 69–88 100 (3.3) 94–100
1 60 (4.0) 46–63 74 (3.8) 68–80
2 49 (4.0) 35–54 66 (3.9) 59–72
3 43 (4.1) 30–51 65 (4.1) 58–71
4 40 (4.3) 26–46 NA NA
5 38 (4.5) 24–44 NA NA
Occlusion
0 70 (3.5) 62–75 98 (3.2) 94–100
1 47 (3.5) 41–51 73 (3.6) 68–75
2 36 (3.6) 28–41 65 (3.7) 60–68
3 30 (3.7) 20–37 63 (3.9) 58–68
4 27 (3.9) 16–34 NA NA
5 25 (4.1) 13–32 NA NA
Note.—Ranges are derived from sensitivity analyses. NA 5 not available.
* Number in parentheses is the standard error.
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within the same treatment group in re-
ported patency rates that was explained
neither by the percentage of subjects
with critical ischemia nor by the percent-
age of subjects with an occlusion. A pos-
sible explanation for this may be related
to study differences that were not ex-
plored in the current analysis, such as
differences in lesion length, diabetic sta-
tus, surveillance program, materials used,
type of stent, and skill of the radiologists
performing the intervention. Although
we extracted information on lesion
length, we were unable to classify these
in meaningful groups because of the dif-
ferent reporting methods used. For exam-
ple, some authors reported the lesion
length as the proportion of lesions larger
than 3 cm or some other arbitrarily cho-
sen cutoff length, whereas others re-
ported the range of lesion length or the
mean or median lesion length with or
without the standard deviation, making
comparison of studies with regard to le-
sion length difficult. The influence of dis-
tal arterial runoff status and differences
in definition of patency were explored in
the current study. In the multivariate
analysis, these influences were not statis-
tically significant. An explanation for
this may be related to the fact that only a
limited number of studies were included
in the analyses, and, therefore, the power
may have been too low to enable detec-
tion of the influences associated with
these factors. The lack of a statistically
significant contribution associated with
runoff status may also be explained by
the other determinants that were incor-
porated in the multivariate regression
model. Clinical indication and lesion
type are probably stronger prognostic
factors than runoff status and may, there-
fore, capture the prognostic information
associated with runoff status.
Third, the meta-analytic technique
that we used in the current study has
advantages and disadvantages (17). The
main advantage is that it allows adjust-
ment for differences in case mix of the
study populations. A disadvantage is that
it does not incorporate a random compo-
nent in treatment effect, which may
yield pooled patency data that seem
more precise than if a meta-analytic tech-
nique had been used that does incorpo-
rate a random effect. However, the large
differences in the study populations ana-
lyzed and the possibility that this
method offers to explain observed differ-
ences in treatment effect outweigh the
lack of a random-effects component.
Fourth, the majority of studies ana-
lyzed were nonexperimental cohort stud-
ies, and in only one study were patients
randomly assigned to treatment groups.
This implies that the population under-
going stent implantation may differ from
the population undergoing balloon dila-
tion. Although we corrected for some of
the differences in case mix, it should be
noted that the treatment indication in a
large proportion of patients undergoing
stent implantation was to salvage a failed
balloon dilation procedure, which sug-
gests that the lesions in those who under-
went stent implantation were probably
more difficult to treat, and this may lead
to an underestimation of the stent im-
plantation results. To explore the possi-
ble influence of this selection bias on our
results, we performed a sensitivity analy-
sis in which we excluded the studies that
reported primary stent implantation re-
sults. In other words, we excluded studies
that were unlikely to be affected by selec-
Figure 2. Cumulative primary patency rates and 95% CIs (error bars) for femoropopliteal
balloon dilation (}) and femoropopliteal stent implantation (E), depending on lesion type
(stenosis vs occlusion) and clinical indication (claudication vs critical ischemia). A, Graph shows
that the estimates for the primary patency following percutaneous transluminal angioplasty and
stent placement are similar in patients with claudication and a femoropopliteal stenosis.
B–D, Graphs show that the estimates for the primary patency following percutaneous translu-
minal angioplasty and stent placement are different in patients with critical ischemia and in
patients with a femoropopliteal occlusion.
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tion bias and we assessed the influence
on our results. The estimated patency
rates associated with stent implantation
did not differ substantially from our base-
line results, suggesting that selection
probably did not lead to an underestima-
tion of patency results associated with
stent implantation. Furthermore, despite
possible underestimation, we still found
stent implantation to yield higher pa-
tency results than balloon dilation. Thus,
correcting for selection bias would sup-
port our conclusions.
To our knowledge, only three random-
ized clinical trials comparing balloon di-
lation and stent implantation have been
published so far (5,10,35). Of these, only
one met our inclusion criteria. In con-
trast to the results of the current study,
no significant difference between femo-
ropopliteal balloon dilation and stent
implantation for the treatment of critical
ischemia or occlusion was detected in
these clinical trials. A possible explana-
tion may be that the trials were of limited
sample size (range, 32–70 subjects) and
had a maximum follow-up of only 1 year.
Another explanation may be that the two
larger randomized clinical trials included
mainly patients with claudication (77%–
100% of patients had claudication) and
stenosis (61%–82% had a stenosis),
which may result in a dilution of the
difference between stent placement and
balloon dilation that was observed only
in the subgroup of patients with critical
ischemia or occlusion.
None of the stent implantation studies
included in the current analysis were
stratified for clinical indication. In two
studies, the authors reported a statisti-
cally significant lower patency rate after
stent implantation for an occlusion,
compared with the rate after stent im-
plantation for a stenosis (20,21). It is pos-
sible that a meta-analysis that aggregates
data at an overall group level would fail
to demonstrate findings relevant for spe-
cific patient groups. We did, however,
detect the influence of critical ischemia
and lesion type on the results after bal-
loon dilation. Furthermore, in a sensitiv-
ity analysis, we explored the effect of in-
cluding patency rates reported for the
subgroups of occlusion and stenosis
(these were available in one balloon dila-
tion study and in the two stent studies
reporting a statistically significant differ-
ence) instead of the reported overall pa-
tency result. This did not change our re-
sults.
Our conclusions should be viewed in
the light of study-design considerations
and clinical implications for the patient.
The results of this analysis of published
articles on stent implantation and bal-
loon dilation for femoropopliteal arterial
disease suggest that stent implantation is
a useful adjunct to balloon dilation and
that in the treatment of occlusions and
critical ischemia, stent implantation may
be associated with more favorable long-
term results, as compared with balloon
dilation results. Publication bias, how-
ever, cannot be ruled out. A potential
clinical concern associated with place-
ment of a femoropopliteal stent is that
among the failures following a technical
successful stent placement, relatively
more patients seem to develop thrombo-
sis that may require more extensive treat-
ment than among the failures following
a technically successful balloon dilation
(5,6,10,35). This higher risk for thrombo-
sis, however, does not seem to result in
lower primary 1-year patency rates, as
compared with the balloon dilation re-
sults. Nevertheless, the potential risk may
increase the inconvenience to the pa-
tient. The question remains whether the
higher long-term patency rates after stent
implantation for the treatment of critical
ischemia and occlusion, as compared
with those after balloon dilation, coun-
terbalance the higher risk of thrombosis
after stent implantation, relative to the
risk associated with balloon dilation.
In conclusion, stent placement is a use-
ful bailout procedure to save a failed fem-
oropopliteal balloon dilation procedure.
More research seems necessary to com-
pare the influence of disease severity on
the outcomes of femoropopliteal balloon
dilation and primary stent implantation
and on the effects of successful treat-
ment, treatment failure, and thrombosis
after these interventions on the patients
well-being.
STATISTICAL CONSULTANT
COMMENTARY
Any number of biases may arise in the syn-
thesis of information from a wide range of
studies purporting to address the same is-
sue. Meta-analysis is one quantitative
method to systematically pool all the avail-
able information regarding a medical tech-
nique. This statistical method combines
measures of effect size—a single comparable
index of the effectiveness of an interven-
tion—across all the independent trials that
have addressed the issue. In theory, this
sounds good; we act “as if” we could per-
form a single multicenter experiment based
on all the subject information gathered in
multiple independent trials.
When performing a meta-analysis, one
typically begins by locating all the studies
in the area of interest. There are various
ways to do this: for instance, a Web-based
search of the literature. Mosteller and
Chalmers (Stat Sci 1992; 7:227–236) report
in their reviews of the meta-analysis litera-
ture that “We know that computer searches
alone still find less than two-thirds of the
relevant trials.” As a result, one can never be
sure that the authors of a review have lo-
cated all the relevant studies. One potential
source of bias in this process is publication
bias. That is, it may be that all the relevant
studies are not published in the literature.
There are any number of reasons why a
study was not published (JAMA 1990; 263:
1385–1389). Studies with “negative” find-
ings may not be submitted to journals, or
editors may not be enthusiastic about pub-
lishing contradictory studies. Statistically
nonsignificant findings also may be less
publishable. Justification for nonsubmis-
sion or nonacceptance may include a small
sample size or the lack of randomization
(Lancet 1991; 337:867–872). Even if such a
study is publicly presented, it may be pub-
lished in a format that is “below the radar”
of the literature search (eg, symposium pre-
sentations, posters, meeting abstracts). In
actuality, it is not necessary for all relevant
studies to be included in a meta-analysis. A
sample of results that represents the effect
magnitude is all that is required. Any non-
random selection process (as opposed to a
random sampling process) will result in es-
timates that are debatable and sometimes
false.
Publication bias is probably impossible to
eliminate, but one technique for detecting
it is the inverted funnel plot, as described by
Egger and colleagues (BMJ 1997; 315:629–
634) and Light and Pillemer (Summing Up:
The Science of Reviewing Research. Cam-
bridge, Mass: Harvard University Press,
1984). With funnel plots, we begin by as-
suming that larger studies of the effect of an
intervention are more precise and thus
more likely to be published. The results of
smaller studies will be less precise, and thus
their estimated effect size will vary consid-
erably. A funnel plot is a scatterplot of the
results of all studies used in a meta-analysis.
The effect size (usually a log odds ratio or
standardized difference) is plotted on the
horizontal axis, and the weight of the study
(usually the reciprocal of the standard error
or the sample size) is plotted on the vertical
axis. If publication bias is absent, then the
plot looks like an inverted funnel, with
most of the smaller studies scattered sym-
metrically at the bottom of the graph. If
there is bias, then the lack of negative small
studies will result in an asymmetric plot. To
some extent, it is possible to correct for pub-
lication bias, although it is best to make the
effort to avoid it.
Publication bias is but one difficulty to be
surmounted by those who wish to review
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research findings. Ultimately, the best test
of the question is a single, well-controlled
trial. Egger et al (BMJ 1997; 315:629–634)
reported that in eight cases where a pub-
lished meta-analysis was compared to a sub-
sequent clinical trial, the findings of the
meta-analysis were concordant in half the
cases. “In all cases discordance was due to
meta-analysis showing larger effects. Fun-
nel plot asymmetry was present in three out
of four discordant pairs but in none of the
concordant pairs.”
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